Background: Invasive mold diseases (IMDs) cause severe illness, but public health surveillance data are lacking. We describe data collected from a laboratory-based, pilot IMD surveillance system. Methods: During 2017-2019, the Emerging Infections Program conducted active IMD surveillance at 3 Atlanta-area hospitals. We ascertained potential cases by reviewing histopathology, culture, and Aspergillus galactomannan results and classified patients as having an IMD case (based on European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group [MSG] criteria) or a non-MSG IMD case (based on the treating clinician's diagnosis and use of mold-active antifungal therapy). We described patient features and compared patients with MSG vs non-MSG IMD cases. Results: Among 304 patients with potential IMD, 104 (34.2%) met an IMD case definition (41 MSG, 63 non-MSG). The most common IMD types were invasive aspergillosis (n = 66 [63.5%]), mucormycosis (n = 8 [7.7%]), and fusariosis (n = 4 [3.8%]); the most frequently affected body sites were pulmonary (n = 66 [63.5%]), otorhinolaryngologic (n = 17 [16.3%]), and cutaneous/deep tissue (n = 9 [8.7%]). Forty-five (43.3%) IMD patients received intensive care unit-level care, and 90-day all-cause mortality was 32.7%; these outcomes did not differ significantly between MSG and non-MSG IMD patients. Conclusions: IMD patients had high mortality rates and a variety of clinical presentations. Comprehensive IMD surveillance is needed to assess emerging trends, and strict application of MSG criteria for surveillance might exclude over one-half of clinically significant IMD cases. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Background: Invasive mold diseases (IMDs) cause severe illness, but public health surveillance data are lacking. We describe data collected from a laboratory-based, pilot IMD surveillance system. Methods: During 2017-2019, the Emerging Infections Program conducted active IMD surveillance at 3 Atlanta-area hospitals. We ascertained potential cases by reviewing histopathology, culture, and Aspergillus galactomannan results and classified patients as having an IMD case (based on European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group [MSG] criteria) or a non-MSG IMD case (based on the treating clinician's diagnosis and use of mold-active antifungal therapy). We described patient features and compared patients with MSG vs non-MSG IMD cases. Results: Among 304 patients with potential IMD, 104 (34.2%) met an IMD case definition (41 MSG, 63 non-MSG). The most common IMD types were invasive aspergillosis (n = 66 [63.5%]), mucormycosis (n = 8 [7.7%]), and fusariosis (n = 4 [3.8%]); the most frequently affected body sites were pulmonary (n = 66 [63.5%]), otorhinolaryngologic (n = 17 [16.3%]), and cutaneous/deep tissue (n = 9 [8.7%]). Forty-five (43.3%) IMD patients received intensive care unit-level care, and 90-day all-cause mortality was 32.7%; these outcomes did not differ significantly between MSG and non-MSG IMD patients. Conclusions: IMD patients had high mortality rates and a variety of clinical presentations. Comprehensive IMD surveillance is needed to assess emerging trends, and strict application of MSG criteria for surveillance might exclude over one-half of clinically significant IMD cases. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Rosemary A Barnes; P Lewis White; C Oliver Morton; Thomas R Rogers; Mario Cruciani; Juergen Loeffler; J Peter Donnelly Journal: Med Mycol Date: 2018-04-01 Impact factor: 4.076
Authors: Martin Hoenigl; Jon Salmanton-García; Thomas J Walsh; Marcio Nucci; Chin Fen Neoh; Jeffrey D Jenks; Michaela Lackner; Rosanne Sprute; Abdullah M S Al-Hatmi; Matteo Bassetti; Fabianne Carlesse; Tomas Freiberger; Philipp Koehler; Thomas Lehrnbecher; Anil Kumar; Juergen Prattes; Malcolm Richardson; Sanjay Revankar; Monica A Slavin; Jannik Stemler; Birgit Spiess; Saad J Taj-Aldeen; Adilia Warris; Patrick C Y Woo; Jo-Anne H Young; Kerstin Albus; Dorothee Arenz; Valentina Arsic-Arsenijevic; Jean-Philippe Bouchara; Terrence Rohan Chinniah; Anuradha Chowdhary; G Sybren de Hoog; George Dimopoulos; Rafael F Duarte; Petr Hamal; Jacques F Meis; Sayoki Mfinanga; Flavio Queiroz-Telles; Thomas F Patterson; Galia Rahav; Thomas R Rogers; Coleman Rotstein; Retno Wahyuningsih; Danila Seidel; Oliver A Cornely Journal: Lancet Infect Dis Date: 2021-02-16 Impact factor: 25.071
Authors: Shawn R Lockhart; Cau D Pham; Lalitha Gade; Naureen Iqbal; Christina M Scheel; Angela A Cleveland; Anne M Whitney; Judith Noble-Wang; Tom M Chiller; Benjamin J Park; Anastasia P Litvintseva; Mary E Brandt Journal: J Clin Microbiol Date: 2013-06-12 Impact factor: 5.948
Authors: Paul E Verweij; Bart J A Rijnders; Roger J M Brüggemann; Elie Azoulay; Matteo Bassetti; Stijn Blot; Thierry Calandra; Cornelius J Clancy; Oliver A Cornely; Tom Chiller; Pieter Depuydt; Daniele Roberto Giacobbe; Nico A F Janssen; Bart-Jan Kullberg; Katrien Lagrou; Cornelia Lass-Flörl; Russell E Lewis; Peter Wei-Lun Liu; Olivier Lortholary; Johan Maertens; Ignacio Martin-Loeches; M Hong Nguyen; Thomas F Patterson; Thomas R Rogers; Jeroen A Schouten; Isabel Spriet; Lore Vanderbeke; Joost Wauters; Frank L van de Veerdonk Journal: Intensive Care Med Date: 2020-06-22 Impact factor: 17.440
Authors: Nico A F Janssen; Rémy Nyga; Lore Vanderbeke; Cato Jacobs; Mehmet Ergün; Jochem B Buil; Karin van Dijk; Josje Altenburg; Catherine S C Bouman; Hans I van der Spoel; Bart J A Rijnders; Albert Dunbar; Jeroen A Schouten; Katrien Lagrou; Marc Bourgeois; Marijke Reynders; Niels van Regenmortel; Lynn Rutsaert; Piet Lormans; Simon Feys; Yves Debavaye; Fabienne Tamion; Damien Costa; Julien Maizel; Hervé Dupont; Taieb Chouaki; Saad Nseir; Boualem Sendid; Roger J M Brüggemann; Frank L van de Veerdonk; Joost Wauters; Paul E Verweij Journal: Emerg Infect Dis Date: 2021-09-14 Impact factor: 6.883
Authors: Kaitlin Benedict; Jeremy A W Gold; Emily N Jenkins; Jeremy Roland; Devra Barter; Christopher A Czaja; Helen Johnston; Paula Clogher; Monica M Farley; Andrew Revis; Lee H Harrison; Laura Tourdot; Sarah Shrum Davis; Erin C Phipps; Christina B Felsen; Brenda L Tesini; Gabriela Escutia; Rebecca Pierce; Alexia Zhang; William Schaffner; Meghan Lyman Journal: Open Forum Infect Dis Date: 2022-09-07 Impact factor: 4.423